Prulifloxacin

Summary

Prulifloxacin (CHEMBL422648) is a phase-3 clinical-stage small molecule (ATC J01MA17); indicated across 5 conditions including chronic bronchitis and urinary tract infection.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: J01MA17
• Indications: 5 conditions
• Clinical trials: 7
• Chemistry: 461.5 Da · C21H20FN3O6S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL422648
Name	Prulifloxacin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	65947
ATC	J01MA17
Molecular formula	C21H20FN3O6S
Molecular weight	461.5
InChIKey	PWNMXPDKBYZCOO-UHFFFAOYSA-N

SMILES: CC1N2C3=CC(=C(C=C3C(=O)C(=C2S1)C(=O)O)F)N4CCN(CC4)CC5=C(OC(=O)O5)C

IUPAC name: 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]piperazin-1-yl]-4-oxo-1H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid

Also known as: NM-441, NM441, NSC-759833, Prulifloxacin, Prulifloxacine, Prulifloxacino, Pruvel, Sword, SID26758037, PRULIFLOXACINE, SID144205788, SID170465849

Patent coverage: 58 distinct patent families (128 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 104 (81%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prelamin-A/C.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
chronic bronchitis	3	MONDO:0005607	EFO:0006505
urinary tract infection	3	MONDO:0100338	EFO:0003103
gastroenteritis	3	MONDO:0002269	EFO:1001463
bacterial infectious disease	3	MONDO:0005113	EFO:0000771
prostatitis	2	MONDO:0005280	EFO:0003830

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	4
PHASE2	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00392574	PHASE3	COMPLETED	Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler’s Diarrhea
NCT00448422	PHASE3	COMPLETED	Safety and Efficacy of Prulifloxacin vs Placebo in Treatment of Acute Gastroenteritis in Adult Travelers
NCT02157571	PHASE3	UNKNOWN	A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Exacerbations of Chronic Bronchitis With Levofloxacin Hydrochloride Tablet as Active Control
NCT02439632	PHASE3	COMPLETED	A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet as Active Control
NCT01231737	PHASE2	UNKNOWN	Efficacy of Two Prophylactic Schedules (Prulifloxacin Versus Phosphomycin)
NCT03201796	PHASE2	COMPLETED	Prulifloxacin in Chronic Bacterial Prostatitis (CBP)
NCT03032692	Not specified	COMPLETED	Motor Task Performance Under Visual and Auditory Feedback Post Stroke: a Randomized Crossover Trial

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).